⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893331 | 0.72 | NFE2L2 (0.62) | — | |
| SCHEMBL6042142 | 0.72 | NOTUM (0.77) | — | |
| SCHEMBL1002244 | 0.71 | IP6K1 (0.53) | — | |
| SCHEMBL9199411 | 0.70 | — | — | |
| SCHEMBL24517467 | 0.69 | — | — | |
| SCHEMBL28265713 | 0.69 | HDAC6 (0.45) | — | |
| SCHEMBL1931574 | 0.69 | HSD17B10 (0.52) | — | |
| SCHEMBL13071189 | 0.68 | — | — | |
| SCHEMBL23104502 | 0.68 | — | — | |
| SCHEMBL608199 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2025-03-06 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025011476-A1 | INDAZOLE DERIVATIVE OR PHARMACEUTICAL SALT THEREOF AND USE THEREOF | 浙江大学 | 2025-01-16 | — | — | WO | disclosed |
| EP-4490159-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119219609-A | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof | 浙江大学 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20180201600-A1 | NITROGEN-CONTAINING HETEROCYCLES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014202027-A1 | SPIROCYCLIC DERIVATIVE OF 4,5-DIHYDROPYRAZOLO[3,4-C]PYRIDINE-2-ONE, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 (CN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-5284838-A | Hypotensive agents | ELF SANOFI (FR) | 1994-02-08 | — | — | US | disclosed |